LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.3 USD -1.52% Market Closed
Market Cap: 34.2m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

LVTX Price Targets Summary
LAVA Therapeutics NV

Wall Street analysts forecast LVTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LVTX is 2.21 USD with a low forecast of 1.52 USD and a high forecast of 3.15 USD.

LVTX Lowest Forecast
Wall Street Target
1.52 USD
17% Upside
LVTX Average Forecast
Wall Street Target
2.21 USD
70% Upside
LVTX Highest Forecast
Wall Street Target
3.15 USD
142% Upside
Lowest
Price Target
1.52 USD
17% Upside
Average
Price Target
2.21 USD
70% Upside
Highest
Price Target
3.15 USD
142% Upside
LAVA Therapeutics NV Competitors:
Price Targets
300406
Beijing Strong Biotechnologies Inc
44% Upside
M
MAB
Mabion SA
20% Downside
AUPH
Aurinia Pharmaceuticals Inc
22% Upside
IGMS
IGM Biosciences Inc
85% Upside
300406
Beijing Strong Biotechnologies Inc
44% Upside
M
MAB
Mabion SA
20% Downside
AUPH
Aurinia Pharmaceuticals Inc
22% Upside
IGMS
IGM Biosciences Inc
85% Upside
068270
Celltrion Inc
31% Upside
VRTX
Vertex Pharmaceuticals Inc
0% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
33% Upside
2616
CStone Pharmaceuticals
33% Downside

Revenue
Forecast

Revenue Estimate
LAVA Therapeutics NV

For the last 3 years the compound annual growth rate for LAVA Therapeutics NV's revenue is 25%. The projected CAGR for the next 4 years is -29%.

25%
Past Growth
-29%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
LAVA Therapeutics NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
LAVA Therapeutics NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

See Also

Summary
LVTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LVTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LVTX stock valuation using valuation multiples.
Wall Street Estimates
LVTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LVTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LVTX's stock price target?
Price Target
2.21 USD

According to Wall Street analysts, the average 1-year price target for LVTX is 2.21 USD with a low forecast of 1.52 USD and a high forecast of 3.15 USD.

What is LAVA Therapeutics NV's Revenue forecast?
Projected CAGR
-29%

For the last 3 years the compound annual growth rate for LAVA Therapeutics NV's revenue is 25%. The projected CAGR for the next 4 years is -29%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 240,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.